Document:

Exhibit 4.2

 

THIS WARRANT AND THE
ORDINARY SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED
UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”) SHALL
HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE 1933 ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR
IS SUCH TRANSFER IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. THIS LEGEND SHALL BE ENDORSED UPON ANY WARRANT ISSUED IN
EXCHANGE FOR THIS WARRANT OR ANY ORDINARY SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT.

 

WARRANT TO PURCHASE SHARES OF

ORDINARY SHARES

 

OF

 

HEALTH SCIENCES ACQUISITIONS CORPORATION
2

 

_________________,
2020

 

W-__________-___

 

This is to Certify
That, FOR VALUE RECEIVED, HSAC 2 HOLDINGS, LLC, or his, her or its assigns (“Holder”), is entitled to purchase,
subject to the provisions of this Warrant, from HEALTH SCIENCES ACQUISITIONS CORPORATION 2, Cayman
Islands exempted company (the “Company”), 1,500,000 fully paid, validly issued and nonassessable ordinary
shares of the Company, par value $0.0001 per share (the “Ordinary Shares”) at a price of $11.50 per share. The
number of Ordinary Shares to be received upon the exercise of this Warrant and the price to be paid for each Ordinary Share may
be adjusted from time to time as hereinafter set forth. The Ordinary Shares deliverable upon such exercise, as adjusted from time
to time, are hereinafter sometimes referred to as “Warrant Shares,” and the exercise price for an Ordinary Share
in effect at any time, as adjusted from time to time, is hereinafter sometimes referred to as the “Exercise Price.”

 

(a) EXERCISE
OF WARRANT. This Warrant may be exercised in whole or in part at any time on the later of (i) 30 days after the consummation by
the Company of its initial merger, share exchange, asset acquisition, share purchase, reorganization or other similar business
combination with one or more businesses or entities (the “Business Combination”) (as described more fully in
the Registration Statement on Form S-1 (No. 333-239922) as filed with the Company or (ii) 12 months from the closing of the public
offering of the Company’s Ordinary Shares, and terminating at 5:00 p.m., New York City time on five years from the consummation
of the Business Combination (the “Expiration Date”). Each Warrant not exercised on or before the Expiration
Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close
of business on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the
Expiration Date; provided, however, that the Company will provide at least twenty (20) days’ prior written notice of any
such extension to registered holders of the Warrants and, provided further that any such extension shall be identical in duration
among all the Warrants.

 

    	 	 	 

     

    

 

(1) This
Warrant may be exercised by presentation and surrender hereof to the Company at its principal office with the Purchase Form annexed
hereto (the “Purchase Form”) duly executed and accompanied by payment of the Exercise Price for the number of
Warrant Shares specified in such Purchase Form (which may take the form of a “cashless exercise” pursuant to Section
(a)(2) if so indicated in the Purchase Form).

 

(2) The
Holder shall pay the Exercise Price in immediately available funds; provided, however, that the Holder may, in the Holder’s
sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise”, in which event the
Company shall issue to the Holder the number of Warrant Shares determined as follows:

 

X = Y(A-B)/A

 

where

 

X = the number of Warrant Shares to
be issued to the Holder.

 

Y = the total number of Warrant Shares
with respect to which this Warrant is being exercised.

 

A = the Fair Market Value (as defined
below) of one Ordinary Share on the trading day immediately preceding the date on which Holder elects to exercise this Warrant
by means of a “cashless exercise.”

 

B = the Exercise Price then in effect
for the applicable Warrant Shares at the time of such exercise.

 

For purposes of this Warrant, “Fair
Market Value” means, for any security as of any date, the price determined by the first of the following clauses that applies:
(a) if the Ordinary Shares are then listed on a national securities exchange, the daily volume weighted average price of the Ordinary
Shares for such date (or the nearest preceding date) on the trading market on which the Ordinary Shares are then listed as reported
by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (b)  if
the Ordinary Shares are quoted on the OTC Bulletin Board or the OTC Market, the average closing bid price on such market for the
five most recently completed trading days, (c) if paragraphs (a) or (b) are not applicable, if an appraiser hired by the Company
has provided a report on the fair market value of an Ordinary Share within the 12-month period preceding the date on which Holder
elects to exercise this Warrant by means of a “cashless exercise,” the fair market value of a share of Ordinary Shares
as determined by such appraiser, or (d) if none of the foregoing is applicable, the price determined by the Board of Directors
of the Company in good faith.

 

(b) Effective
Time of Exercise. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of
business on the day on which the Purchase Form has been delivered to the Company (the “Exercise Date”) as provided
in Section (a). At such time, the person or persons in whose name or names any certificates for Warrant Shares shall be
issuable upon such exercise as provided in Section (c) below shall be deemed to have become the holder or holders of record
of the Warrant Shares represented by such certificates. Notwithstanding the foregoing, if the Holder or any assignee does not enter
into the Stockholders’ Agreement within three (3) business days of being requested to do so by the Company, then the exercise
of this Warrant will be deemed to not have been effective and void ab initio and the Holder or any assignee shall return any securities
received by them pursuant to Section (c) to the Company.

 

    	 	 2	 

     

    

 

(c) Delivery
to Holder.

 

(1) As
soon as practicable after the exercise of this Warrant in whole or in part, and in any event within five (5) business days thereafter,
the Company will cause to be issued in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder
of any applicable transfer taxes) may direct:

 

(A) a
certificate or certificates for the number of Warrant Shares to which such Holder shall be entitled, and

 

(B) in
case such exercise is in part only, a new warrant or warrants of like tenor, exercisable for in the aggregate the number of Ordinary
Shares equal (giving effect to any adjustment therein) to the number of Ordinary Shares called for on the face of this Warrant
minus the number of such shares purchased by the Holder upon such exercise.

 

(2) To
the extent permitted by law and except as provided in this Warrant, the Company’s obligations to issue and deliver Warrant
Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder
to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person
or entity or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach
or alleged breach by the Holder or any other person or entity of any obligation to the Company or any violation or alleged violation
of law by the Holder or any other person or entity, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing Warrant
Shares upon exercise of the Warrant as required pursuant to the terms hereof.

 

(d) RESERVATION
OF SHARES. The Company shall at all times reserve for issuance and/or delivery upon exercise of this Warrant such number of Ordinary
Shares (as adjusted pursuant to the terms hereof) as shall be required for issuance and delivery upon exercise of this Warrant.
The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable
Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The
Company will take all such action as may be reasonably necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation
system upon which the Ordinary Shares may be listed.

 

    	 	 3	 

     

    

 

(e) FRACTIONAL
SHARES. No fractional shares or scrips representing fractional shares shall be issued upon the exercise of this Warrant. With respect
to any fraction of a share called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to
such fraction multiplied by the fair market value of an Ordinary Share.

 

(f) LOSS
OR DESTRUCTION OF WARRANT. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation
of this Warrant, and (in the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender
and cancellation of this Warrant, if mutilated, the Company will execute and deliver a new Warrant of like tenor and date.

 

(g) RIGHTS
OF THE HOLDER. The Holder shall not, by virtue hereof, be entitled to any rights of a shareholder in the Company, either at law
or equity, and the rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company
except to the extent set forth herein.

 

(h) CERTAIN
ADJUSTMENTS. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from
time to time as set forth in this Section (h).

 

(1) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Ordinary
Shares or otherwise makes a distribution on any class of capital stock that is payable in Ordinary Shares, (ii) subdivides its
outstanding Ordinary Shares into a larger number of shares, or (iii) combines its outstanding Ordinary Shares into a smaller number
of shares, then, in each such case, the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number
Ordinary Shares outstanding immediately before such event and the denominator of which shall be the number of Ordinary Shares outstanding
immediately after such event. Any adjustment made pursuant to this Section (h)(1) shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant
to clause (ii) or (iii) of this Section (h)(1) shall become effective immediately after the effective date of such subdivision
or combination.

 

(2) Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section (h)(1), the number of Warrant
Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the
same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

    	 	 4	 

     

    

 

(3) Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company
with or into another Person, (ii) the Company effects any sale of all or substantially all of its assets or a majority of its Ordinary
Shares is acquired by a third party, in each case, in one or a series of related transactions, (iii) any tender offer or exchange
offer (whether by the Company or a third party that is conducting such an offer pursuant to an agreement or arrangement with the
Company) is completed pursuant to which all or substantially all of the holders of Ordinary Shares Stock are permitted to tender
or exchange their shares for other securities, cash or property, or (iv) the Company effects any reorganization or reclassification
of Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged
for other securities, cash or property (other than as a result of a subdivision or combination of Ordinary Shares covered by Section
(h)(1) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the right thereafter
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations
on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any such Fundamental
Transaction unless prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or
the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or Person shall assume the obligation
to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled
to receive, and the other obligations under this Warrant. The provisions of this Section (h)(3) shall similarly apply to
subsequent transactions analogous of a Fundamental Transaction type.

 

(4) Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section (h), the Company at its expense will, at
the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number
or type of Warrant Shares or other property issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the
Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

(5) Notices
To Warrant Holders. So long as this Warrant shall be outstanding, (i) if the Company shall pay any dividend or make any distribution
of cash, securities or other property in respect of its Ordinary Shares or (ii) if the Company shall offer to the holders
of Ordinary Shares for subscription or purchase by them any share of any class or any other rights or (iii) if any capital
reorganization of the Company, reclassification of the capital stock of the Company, consolidation or merger of the Company with
or into another corporation, sale, lease or transfer of all or substantially all of the property and assets of the Company to another
corporation, if the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for
any Fundamental Transaction (each as defined below) , or voluntary or involuntary dissolution, liquidation or winding up of the
Company shall be effected, then in any such case, the Company shall cause to be mailed to the Holder, at least fifteen days prior
the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action
and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution or rights, or (y) such
reclassification, reorganization, consolidation, merger, conveyance, lease, Fundamental Transaction, sales or issuances, dissolution,
liquidation or winding up is to take place and the date, if any is to be fixed, as of which the holders of Ordinary Shares or other
securities shall receive cash or other property deliverable upon such reclassification, reorganization, consolidation, merger,
conveyance, lease, Fundamental Transaction, sales or issuances, dissolution, liquidation or winding up.

 

    	 	 5	 

     

    

 

(i) NOTICES.
Any notice or request hereunder shall be in writing and may be given only by, and shall be deemed to have been received upon: (a)
registered or certified mail, return receipt requested, on the date on which such notice or request is received as indicated in
such return receipt; (b) delivery by a nationally recognized overnight courier, one business day after deposit with such courier;
or (c) facsimile or other electronic transmission upon telephone or further electronic communication from the recipient acknowledging
receipt (whether automatic or manual from recipient) of such facsimile or other electronic transmission. In the case of the Company,
such notices and communications shall be addressed to Health Sciences Acquisitions Corporation 2, 40 10th Avenue, Floor 7, New
York, NY 10014, Attn: Alice Lee, Secretary, unless the Company shall notify the Holder that notices and communications should be
sent to a different address (or facsimile number or electronic mail address), in which case such notices and communications shall
be sent to the address (or facsimile number or electronic mail address) specified by the Company. In the case of the Holder, such
notices and communications shall be addressed to its address as set forth in the signature page hereto, unless the Holder shall
notify the Company that notices and communications should be sent to a different address (or facsimile number or electronic mail
address), in which case such notices and communications shall be sent to the address (or facsimile number or electronic mail address)
specified by the Holder.

 

(j) NO
NET-CASH SETTLEMENT. Except as otherwise provided herein, in no event will the Holder be entitled to receive a net-cash settlement
or other consideration in lieu of physical settlement in securities.

 

(k) MODIFICATION
OF AGREEMENT. The provisions of this Warrant may from time to time be amended, modified or waived, by the Company and the holder
of this Warrant.

 

(l) CHARGES,
TAXES AND EXPENSES. Issuance and delivery of a reasonable number of certificates representing Ordinary Shares upon exercise of
this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax
or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided,
however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration
of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an affiliate thereof. The Holder
shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.

 

(m) SUCCESSORS
AND ASSIGNS. This Warrant and the rights of the Holder hereunder may not be transferred and/or assigned by the Holder in any way
whatsoever, and no transaction in respect thereof shall be made, either for consideration or for no consideration. This Warrant
may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the parties hereto and the Company’s successors.
Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any person or entity other than the Company
and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in
writing signed by the Company and the Holder, or the Company’s successors.

 

    	 	 6	 

     

    

 

(n) GOVERNING
LAW.

 

THIS WARRANT
SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

 

ANY LEGAL ACTION
OR PROCEEDING WITH RESPECT TO THIS WARRANT SHALL BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK OR OF THE UNITED STATES OF AMERICA
FOR THE SOUTHERN DISTRICT OF NEW YORK, AND, BY EXECUTION AND DELIVERY OF THIS WARRANT, EACH PARTY HEREBY ACCEPTS FOR ITSELF AND
(TO THE EXTENT PERMITTED BY LAW) IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE JURISDICTION OF THE AFORESAID COURTS.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING, WITHOUT LIMITATION, ANY OBJECTION TO THE LAYING OF VENUE OR BASED
ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY SUCH ACTION OR PROCEEDING IN
SUCH RESPECTIVE JURISDICTIONS. THIS SUBMISSION TO JURISDICTION IS NON-EXCLUSIVE AND DOES NOT PRECLUDE A PARTY FROM OBTAINING JURISDICTION
OVER ANOTHER PARTY IN ANY COURT OTHERWISE HAVING JURISDICTION.

 

EACH PARTY
IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING
OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO IT AT THE ADDRESS SPECIFIED HEREIN OR
SUCH OTHER ADDRESS AS IS SPECIFIED PURSUANT TO THE TERMS HEREOF (OR ITS ASSIGNMENT AND ASSUMPTION), SUCH SERVICE TO BECOME
EFFECTIVE 30 DAYS AFTER SUCH MAILING. NOTHING HEREIN SHALL AFFECT THE RIGHT OF A PARTY OR ANY HOLDER TO SERVE PROCESS IN ANY OTHER
MANNER PERMITTED BY LAW OR TO COMMENCE LEGAL PROCEEDINGS OR OTHERWISE PROCEED AGAINST ANOTHER PARTY IN ANY OTHER JURISDICTION.

 

[remainder of page intentionally
left blank]

 

    	 	 7	 

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed as of the date of this Warrant.

 

	 	HEALTH SCIENCES ACQUISITIONS CORPORATION 2
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

Holder:

 

Accepted and Agreed:

 

HSAC 2 HOLDINGS, LLC

 

By: _________________________

Name:

Title:

 

    	 	 8	 

     

    

 

PURCHASE FORM

 

Dated ____________________

 

(1) The
undersigned hereby irrevocably elects to exercise the within Warrant to the extent of purchasing Ordinary Shares of Health Sciences
Acquisitions Corporation 2 (or such number of Ordinary Shares or other securities or property to which the undersigned is entitled
in lieu thereof or in addition thereto under the provisions of the Warrant).

 

		(2)	_______ (a) The undersigned hereby elects to make payment with the enclosed bank draft, certified
check or money order payable to the Company in payment of the exercise price determined under, and on the terms specified in, the
Warrant, or

 

_______ (b)
The undersigned hereby elects to make payment on a cashless basis.

 

(3) The undersigned hereby
irrevocably directs that the said shares be issued and delivered as follows:

 

	Name(s) in Full	 	Address(es)	 	Number of Ordinary Shares (net of any Ordinary shares used to exercise on a cashless basis	 	S.S. or IRS #
	 	 	 	 	 	 	 

 

(4) If the Warrant was not exercised in
full, please check the following: ___

 

The undersigned hereby irrevocably
directs that any remaining portion of the warrant be issued and delivered as follows:

 

	Name(s) in Full	 	Address(es)	 	Number of Shares 	 	S.S. or IRS #
	 	 	 	 	 	 	 

 

____________________________

Signature of Holder

 

_____________________________

Print Name

 

 

9Exhibit 10.1

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND
MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION
OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

	Principal Amount: $300,000.00	Dated as of June 11, 2020

 

Health Sciences Acquisitions Corporation
2, an exempted company incorporated in the Cayman Islands (the “Maker”), promises to pay to the order of HSAC
2 Holdings, LLC, a Delaware limited liability company, or its registered assigns or successors in interest (the “Payee”)
the principal sum of three hundred thousand dollars ($300,000.00) in lawful money of the United States of America, on the terms
and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds
or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance
with the provisions of this Note.

 

	1.	Principal. The principal balance of this Promissory Note (this “Note”) shall be payable promptly
after the date on which the Maker consummates an initial public offering of its securities or the date on which the Company determines
not to conduct an initial public offering of its securities. The principal balance may be prepaid at any time.
	 	 

	2.	Interest. No interest shall accrue on the unpaid principal balance of this Note.
	 	 

	3.	Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection
of any sum due under this Note, including (without limitation) reasonable attorney’s fees, then to the payment in full of
any late charges and finally to the reduction of the unpaid principal balance of this Note.
	 	 

	4.	Events of Default. The following shall constitute an event of default (“Event of Default”):
	 	 

		(a)	Failure to Make Required Payments. Failure by Maker to pay the principal of this Note within five (5) business days
following the date when due.
	 	 	 

		(b)	Voluntary Liquidation, Etc. The commencement by Maker of a proceeding relating to its bankruptcy, insolvency, reorganization,
rehabilitation or other similar action, or the consent by it to the appointment of, or taking possession by, a receiver, liquidator,
assignee, trustee, custodian, sequestrator (or other similar official) for Maker or for any substantial part of its property, or
the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts
become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

 

     

     

    

 

		(c)	Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises
in respect of maker in an involuntary case under any applicable bankruptcy, insolvency or similar law, for the appointing of a
receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) for Maker or for any substantial part of
its property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance of any such decree or order
unstayed and in effect for a period of 60 consecutive days.
	 	 	 

	5.	Remedies.
	 	 

		(a)	Upon the occurrence of an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare
this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable
thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which
are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.
	 	 	 

		(b)	Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note,
and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without
any action on the part of Payee.
	 	 	 

	6.	Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand,
notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings
instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future
laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment,
levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment;
and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of
execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.
	 	 

	7.	Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default,
or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability
of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification
granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may
be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers,
guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

 

    2

     

    

 

	8.	Notices. Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt
requested, (ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service
providing receipted delivery or (iv) sent by facsimile or (v) to the following addresses or to such other address as either party
may designate by notice in accordance with this Section:

 

If to Maker:

Health Sciences Acquisitions Corporation 2

c/o RTW Investments, LP

40 10th Ave., Floor 7

New York, NY 10014

Attn: Sabera Loughran

 

If to Payee:

 

HSAC 2 Holdings, LLC

c/o RTW Investments, LP

40 10th Ave., Floor 7

New York, NY 10014

Attn: Sabera Loughran

 

Notice shall be deemed given on the earlier
of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected
on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery
service.

 

	9.	Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT
OF LAW PROVISIONS THEREOF.
	 	 

	10.	Jurisdiction. The courts of New York have exclusive jurisdiction to settle any dispute arising out of or in connection
with this agreement (including a dispute relating to any non-contractual obligations arising out of or in connection with this
agreement) and the parties submit to the exclusive jurisdiction of the courts of New York.
	 	 

	11.	Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision
in any other jurisdiction.
	 	 

	12.	Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest
or claim of any kind (“Claim”) in or to any amounts contained in the trust account in which the proceeds of
the initial public offering (the “IPO”) conducted by the Maker and the proceeds of the sale of securities in
a private placement to occur prior to the effectiveness of the IPO, as described in greater detail in the registration statement
and prospectus to be filed with the Securities and Exchange Commission in connection with the IPO, will be placed, and hereby agrees
not to seek recourse, reimbursement, payment or satisfaction for any Claim from the trust account or any distribution therefrom
for any reason whatsoever.

 

    3

     

    

 

	13.	Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written
consent of the Maker and the Payee.
	 	 

	14.	Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto
(by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without
the required consent shall be void.
	 	 

	15.	Further Assurance. The Maker shall, at its own cost and expense, execute and do (or procure to be executed and done
by any other necessary party) all such deeds, documents, acts and things as the Payee may from time to time require as may be necessary
to give full effect to this Promissory Note.

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby,
has caused this Note to be duly executed on the day and year first above written.

 

	 	HEALTH SCIENCES ACQUISITIONS CORPORATION 2
	 	 
	 	By:	/s/ Alice Lee
	 	 	Name:	 Alice Lee
	 	 	Title:	Director

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]